DENTSPLY SIRONA (NASDAQ:XRAY) Price Target Lowered to $20.00 at Barrington Research

DENTSPLY SIRONA (NASDAQ:XRAY - Get Free Report) had its target price reduced by equities research analysts at Barrington Research from $24.00 to $20.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has an "outperform" rating on the medical instruments supplier's stock. Barrington Research's price objective indicates a potential upside of 28.29% from the company's current price. Barrington Research also issued estimates for DENTSPLY SIRONA's Q1 2025 earnings at $0.28 EPS, Q4 2025 earnings at $0.55 EPS, FY2025 earnings at $1.86 EPS, Q1 2026 earnings at $0.37 EPS, Q2 2026 earnings at $0.53 EPS, Q3 2026 earnings at $0.57 EPS, Q4 2026 earnings at $0.59 EPS, FY2026 earnings at $2.05 EPS and FY2027 earnings at $2.30 EPS.

Other equities research analysts also recently issued research reports about the stock. Leerink Partners downgraded shares of DENTSPLY SIRONA from an "outperform" rating to a "market perform" rating in a research note on Thursday, November 7th. StockNews.com raised DENTSPLY SIRONA from a "hold" rating to a "buy" rating in a research report on Tuesday, February 18th. Morgan Stanley lowered their target price on DENTSPLY SIRONA from $30.00 to $23.00 and set an "overweight" rating on the stock in a research note on Tuesday, December 17th. Robert W. Baird cut their price target on DENTSPLY SIRONA from $22.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday. Finally, Jefferies Financial Group lowered shares of DENTSPLY SIRONA from a "buy" rating to a "hold" rating and lowered their price objective for the company from $30.00 to $20.00 in a research report on Thursday, January 23rd. Eleven research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, DENTSPLY SIRONA presently has a consensus rating of "Hold" and a consensus price target of $23.58.

DENTSPLY SIRONA Stock Performance

Shares of DENTSPLY SIRONA stock traded down $0.40 during trading on Friday, reaching $15.59. The company's stock had a trading volume of 3,382,554 shares, compared to its average volume of 2,593,609. The firm has a market cap of $3.10 billion, a PE ratio of -7.53, a P/E/G ratio of 1.80 and a beta of 0.96. The company has a 50-day moving average price of $18.77 and a two-hundred day moving average price of $21.39. The company has a current ratio of 1.25, a quick ratio of 0.84 and a debt-to-equity ratio of 0.72. DENTSPLY SIRONA has a fifty-two week low of $15.47 and a fifty-two week high of $34.28.

Insider Activity at DENTSPLY SIRONA

In related news, Director Gregory T. Lucier bought 15,142 shares of the company's stock in a transaction on Monday, March 3rd. The stock was bought at an average cost of $16.51 per share, with a total value of $249,994.42. Following the completion of the acquisition, the director now owns 81,971 shares in the company, valued at approximately $1,353,341.21. This represents a 22.66 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.52% of the company's stock.

Institutional Investors Weigh In On DENTSPLY SIRONA

Institutional investors have recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in DENTSPLY SIRONA by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 20,183,260 shares of the medical instruments supplier's stock worth $383,078,000 after purchasing an additional 65,478 shares during the last quarter. First Eagle Investment Management LLC raised its stake in shares of DENTSPLY SIRONA by 2.5% during the 4th quarter. First Eagle Investment Management LLC now owns 14,500,409 shares of the medical instruments supplier's stock worth $275,218,000 after buying an additional 348,532 shares during the last quarter. Nuance Investments LLC boosted its position in shares of DENTSPLY SIRONA by 25.0% in the 4th quarter. Nuance Investments LLC now owns 13,545,981 shares of the medical instruments supplier's stock worth $257,103,000 after buying an additional 2,708,097 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of DENTSPLY SIRONA by 18.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 12,549,242 shares of the medical instruments supplier's stock worth $238,186,000 after buying an additional 1,975,404 shares in the last quarter. Finally, Fuller & Thaler Asset Management Inc. grew its stake in DENTSPLY SIRONA by 2.8% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 11,539,418 shares of the medical instruments supplier's stock valued at $219,018,000 after acquiring an additional 314,343 shares during the last quarter. Hedge funds and other institutional investors own 95.70% of the company's stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc manufactures and sells various dental products and technologies worldwide. It operates in four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The company offers dental equipment comprising imaging equipment, motorized dental handpieces, treatment centers, other instruments, amalgamators, mixing machines, and porcelain furnaces; and dental CAD/CAM technologies to support dental restorations, such as intraoral scanners, 3-D printers, mills, other software and services, and a full-chairside economical restoration of esthetic ceramic dentistry, as well as DS Core, its cloud-based platform.